Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christophe Marchand

Showing results (1-10 of 110) with videos related to

Pageof 11
Sort By:
Expert Opinion on Investigational Drugs|May 11, 2012
The elvitegravir Quad pill: the first once-daily dual-target anti-HIV tabletChristophe Marchand
Current Medicinal Chemistry. Anti-Cancer Agents|August 17, 2005
Interfacial inhibitors of protein-nucleic acid interactionsYves Pommier, Christophe Marchand
Nature Reviews. Drug Discovery|December 17, 2011
Interfacial inhibitors: targeting macromolecular complexesYves Pommier, Christophe Marchand
Bioorganic & Medicinal Chemistry Letters|August 4, 2015
Interfacial inhibitorsYves Pommier, Evgeny Kiselev, Christophe Marchand
Advances in Pharmacology (San Diego, Calif.)|July 27, 2013
HIV integrase inhibitors: 20-year landmark and challengesMathieu Métifiot, Christophe Marchand, Yves Pommier
Advances in Pharmacology (San Diego, Calif.)|December 19, 2007
HIV-1 integrase inhibitors: update and perspectivesElena A Semenova, Christophe Marchand, Yves Pommier
Current Topics in Medicinal Chemistry|June 15, 2004
HIV-1 integrase inhibitors: a decade of research and two drugs in clinical trialAllison A Johnson, Christophe Marchand, Yves Pommier
Nature Reviews. Drug Discovery|February 25, 2005
Integrase inhibitors to treat HIV/AIDSYves Pommier, Allison A Johnson, Christophe Marchand
Viruses|August 14, 2010
Resistance to integrase inhibitorsMathieu Métifiot, Christophe Marchand, Kasthuraiah Maddali, et al.
Current Topics in Medicinal Chemistry|September 15, 2009
HIV-1 IN inhibitors: 2010 update and perspectivesChristophe Marchand, Kasthuraiah Maddali, Mathieu Métifiot, et al.
Pageof 11

Showing results (1-10 of 110) with videos related to

Sort By:
Pageof 11
Expert Opinion on Investigational Drugs|May 11, 2012
The elvitegravir Quad pill: the first once-daily dual-target anti-HIV tabletChristophe Marchand
Current Medicinal Chemistry. Anti-Cancer Agents|August 17, 2005
Interfacial inhibitors of protein-nucleic acid interactionsYves Pommier, Christophe Marchand
Nature Reviews. Drug Discovery|December 17, 2011
Interfacial inhibitors: targeting macromolecular complexesYves Pommier, Christophe Marchand
Bioorganic & Medicinal Chemistry Letters|August 4, 2015
Interfacial inhibitorsYves Pommier, Evgeny Kiselev, Christophe Marchand
Advances in Pharmacology (San Diego, Calif.)|July 27, 2013
HIV integrase inhibitors: 20-year landmark and challengesMathieu Métifiot, Christophe Marchand, Yves Pommier
Advances in Pharmacology (San Diego, Calif.)|December 19, 2007
HIV-1 integrase inhibitors: update and perspectivesElena A Semenova, Christophe Marchand, Yves Pommier
Current Topics in Medicinal Chemistry|June 15, 2004
HIV-1 integrase inhibitors: a decade of research and two drugs in clinical trialAllison A Johnson, Christophe Marchand, Yves Pommier
Nature Reviews. Drug Discovery|February 25, 2005
Integrase inhibitors to treat HIV/AIDSYves Pommier, Allison A Johnson, Christophe Marchand
Viruses|August 14, 2010
Resistance to integrase inhibitorsMathieu Métifiot, Christophe Marchand, Kasthuraiah Maddali, et al.
Current Topics in Medicinal Chemistry|September 15, 2009
HIV-1 IN inhibitors: 2010 update and perspectivesChristophe Marchand, Kasthuraiah Maddali, Mathieu Métifiot, et al.
Pageof 11